Dr Reddy launches cholesterol-lowering medicine in US market
10 October 2018 | News
The Colesevelam HCI tablet is a generic version of Japanaese pharmaceutical company Daiichi Sankyo's Welchol
Dr Reddy’s Laboratories Ltd. has announced the launch of a cholesterol-lowering medication Colesevelam HCl Tablets in the United States market approved by the US Food and Drug Administration (USFDA).
The Colesevelam HCI tablet is a generic version of Japanese pharmaceutical company Daiichi Sankyo's Welchol.
The WELCHOL brand and generic had an US sale of approximately $ 471 million for the most recent twelve months ending in August 2018 according to IMS Health.
The tablets will be available in 625 mg with 180-count bottle size, Dr Reddy's said in a statement.
After the launching Shares of Dr Reddy's Laboratories climbed about 1 percent in early trade. Shares of the company hit an intraday high of Rs 2,600 on BSE, up as much as 6.3 percent.
